Media stories about Synageva Biopharma Corp (NASDAQ:GEVA) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synageva Biopharma Corp earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.4877041861356 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Synageva Biopharma Corp (GEVA) remained flat at $238.60 during midday trading on Friday. Synageva Biopharma Corp has a 52-week low of $60.19 and a 52-week high of $239.20. The stock has a 50 day moving average of $215.15 and a 200-day moving average of $131.31.
About Synageva Biopharma Corp
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency).
Receive News & Ratings for Synageva Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synageva Biopharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.